Is there a right time to invest in structured products?



Gary Dale, head of intermediary sales for Investec Structured Products, explains how the rarely employed strategy of structured investments can often work best in sideways or falling markets.

Anecdotal feedback and past evidence suggests that when the market hits or approaches ‘historical highs’, investors and/or advisers become wary of investing in structured products, investments or deposits. It is assumed they prefer either cash based savings or other more traditional investments. Given that traditional investment styles require their underlying benchmarks to rise to generate any growth for the investor, I struggle with this point of view. There is, of course, the dividend debate to consider here, but surely equity investors have more sense than to take on full equity mark...

To continue reading this article...

Join Investment Week for free

  • Unlimited access to real-time news, analysis and opinion from the investment industry, including the Sustainable Hub covering fund news from the ESG space
  • Get ahead of regulatory and technological changes affecting fund management
  • Important and breaking news stories selected by the editors delivered straight to your inbox each day
  • Weekly members-only newsletter with exclusive opinion pieces from leading industry experts
  • Be the first to hear about our extensive events schedule and awards programmes

Join now


Already an Investment Week


More on Specialist

While thematic funds offer diversification and a specialist knowledge base, investors must also consider the sensitivity to real bond yields inherent in these funds.

Deep Dive: Thematics offer diversification but investors must consider bond sensitivity

‘Dedicated specialists’

James Baxter-Derrington
clock 06 April 2023 • 4 min read
Deal volumes fell last year as rising interest rates brought the end of cheap money

European private equity yet to spend €270bn worth of capital

Deployment of capital expected

Kathleen Gallagher
clock 04 January 2023 • 1 min read
Ali H. Munawar, CEO of Pledge Therapeutics

Early-stage biopharma: An opportunity for strategic investment

Disproportionately smaller investment

Ali H. Munawar
clock 10 August 2022 • 4 min read